In this interview from the ASRS 2014 Annual Meeting, Dr. Tongalp Tezel shares results from a study on the effect of eplerenone, a mineralocorticod receptor antagonist, in the treatment of central serous chorioretinopathy (CSCR). In the study, 8 patients with CSCR were treated with 50 mg/day of eplerenone. Resulting biologic effects of the drug and final visual acuity were compared with outcomes of 5 untreated patients with CSCR. The study showed that eplerenone significantly speeds up the resolution of subretinal fluid in CSCR, so it may be helpful in patients who desire quicker recovery. Despite better anatomical outcomes, however, the drug does not seem to relieve choroidal congestion or improve final visual acuity.